A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
International students increasingly favor tech-related fields: Report
01/28/2026 03:21 PM - Business
Taiwan shares close up 1.5%
01/28/2026 02:15 PM - Politics
Taiwan, U.S. hold sixth Economic Prosperity Partnership Dialogue
01/28/2026 11:16 AM - Society
Taiwan headline news
01/28/2026 10:50 AM - Business
U.S. dollar down in Taipei trading
01/28/2026 10:21 AM